Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C26H26N8O11S2 |
| Molecular Weight | 690.662 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 2 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=C(COC(=O)N2CC[C@H](C2)N3CC\C(=C/C4=C(N5[C@H](SC4)[C@H](NC(=O)C(=N/O)\C6=NSC(N)=N6)C5=O)C(O)=O)C3=O)OC(=O)O1
InChI
InChIKey=HFTSMHTWUFCYMJ-YIOMYIDASA-N
InChI=1S/C26H26N8O11S2/c1-10-14(45-26(41)44-10)8-43-25(40)32-4-3-13(7-32)33-5-2-11(20(33)36)6-12-9-46-22-16(21(37)34(22)17(12)23(38)39)28-19(35)15(30-42)18-29-24(27)47-31-18/h6,13,16,22,42H,2-5,7-9H2,1H3,(H,28,35)(H,38,39)(H2,27,29,31)/b11-6+,30-15-/t13-,16-,22-/m1/s1
| Molecular Formula | C26H26N8O11S2 |
| Molecular Weight | 690.662 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 2 |
| Optical Activity | UNSPECIFIED |
Ceftobiprole is a fifth-generation cephalosporin antibiotic. It was discovered by Basilea Pharmaceutica and was developed by Johnson & Johnson Pharmaceutical Research and Development. The drug is demonstrates activity against clinically important gram-positive pathogens, including methicillin-resistant Staphylococcus aureus, penicilliin-resistant Staphylococcus pneumoniae, and Enterococcus faecalis. The drug also has demonstrated activity against gram-negative bacteria including Citrobacter spp., Escherichia coli, Enterobacter spp., Klebsiella spp., Serratia marcescens, and Pseudomonas aeruginosa. The drug has gained regulatory authorization from European states for the treatment of hospital-acquired pneumonia (HAP, excluding ventilator-associated pneumonia, VAP) and community-acquired pneumonia (CAP).
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Ceftobiprole activity against over 60,000 clinical bacterial pathogens isolated in Europe, Turkey, and Israel from 2005 to 2010. | 2014-07 |
|
| Prevalence of antimicrobial-resistant pathogens in Canadian hospitals: results of the Canadian Ward Surveillance Study (CANWARD 2008). | 2010-11 |
|
| Non-susceptibility trends among staphylococci from bacteraemias in the UK and Ireland, 2001-06. | 2008-11 |
|
| In vivo pharmacodynamics of ceftobiprole against multiple bacterial pathogens in murine thigh and lung infection models. | 2008-10 |
|
| Activity of ceftobiprole compared with those of other agents against Staphylococcus aureus strains with different resistotypes by time-kill analysis. | 2008-02 |
|
| Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria. | 2008-01 |
|
| Activity of ceftobiprole against community-associated methicillin-resistant Staphylococcus aureus isolates recently recovered from US military trainees. | 2007-12 |
|
| Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae. | 2007-07 |
|
| Clinical profile of ceftobiprole, a novel beta-lactam antibiotic. | 2007-06 |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:10:06 GMT 2025
by
admin
on
Mon Mar 31 18:10:06 GMT 2025
|
| Record UNII |
YXV28V1B07
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-ATC |
J01DI01
Created by
admin on Mon Mar 31 18:10:06 GMT 2025 , Edited by admin on Mon Mar 31 18:10:06 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
100000091689
Created by
admin on Mon Mar 31 18:10:06 GMT 2025 , Edited by admin on Mon Mar 31 18:10:06 GMT 2025
|
PRIMARY | |||
|
8532
Created by
admin on Mon Mar 31 18:10:06 GMT 2025 , Edited by admin on Mon Mar 31 18:10:06 GMT 2025
|
PRIMARY | |||
|
m3223
Created by
admin on Mon Mar 31 18:10:06 GMT 2025 , Edited by admin on Mon Mar 31 18:10:06 GMT 2025
|
PRIMARY | Merck Index | ||
|
YXV28V1B07
Created by
admin on Mon Mar 31 18:10:06 GMT 2025 , Edited by admin on Mon Mar 31 18:10:06 GMT 2025
|
PRIMARY | |||
|
C505439
Created by
admin on Mon Mar 31 18:10:06 GMT 2025 , Edited by admin on Mon Mar 31 18:10:06 GMT 2025
|
PRIMARY | |||
|
SUB25721
Created by
admin on Mon Mar 31 18:10:06 GMT 2025 , Edited by admin on Mon Mar 31 18:10:06 GMT 2025
|
PRIMARY | |||
|
135413544
Created by
admin on Mon Mar 31 18:10:06 GMT 2025 , Edited by admin on Mon Mar 31 18:10:06 GMT 2025
|
PRIMARY | |||
|
C170536
Created by
admin on Mon Mar 31 18:10:06 GMT 2025 , Edited by admin on Mon Mar 31 18:10:06 GMT 2025
|
PRIMARY | |||
|
376653-43-9
Created by
admin on Mon Mar 31 18:10:06 GMT 2025 , Edited by admin on Mon Mar 31 18:10:06 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
METABOLITE ACTIVE -> PRODRUG |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|